Background: Secreted frizzled-related protein 5 (SFRP5) is a recently identified adipokine; however, its functions during pathogenesis of T2DM and obesity remain unclear. This research attempted to investigate associations between circulating SFRP5 and obesity/T2DM.
Materials and Methods: According to diagnosis, 107 patients were assigned as impaired-glucose regulation (IGR) and 111 patients newly-diagnosed as T2DM were assigned as the T2DM group. Meanwhile, 132 subjects with normal-glucose tolerance (NGT) were assigned as the NGT group. Differences in plasma SFRP5 levels among three groups were compared. Correlation between SFRP5 levels and different metabolic markers was analyzed. Multiple-linear stepwise regression analyses were performed to determine independent factors for SFRP5. Patients in the T2DM group were administrated with metformin for 12 weeks. Meanwhile, changes in plasma SFRP5 levels were also analyzed.
Results: Plasma SFRP5 level of the IGR group was significantly lower compared to the NGT group (219.1± 39.7 pg/mL vs 236.7± 72.6 pg/mL, P < 0.05), however, that of the T2DM group was significantly lower compared to the IGR group (203.5± 42.1 pg/mL vs 219.1± 39.7 pg/mL, P < 0.01). Level of plasma SFRP5 was negatively correlated with fasting plasma glucose, BMI, waist circumference (WC), normalized WC (waist-to-height ratio) (WHtR), 2h plasma glucose, fasting insulin, glycosylated hemoglobin (HbA1c), fasting C-peptide, HOMA-IR, and hs-CRP (P < 0.01). Among the above factors, HbA1c and fasting insulin levels (FIns) were two independent factors. Plasma SFRP5 levels were increased after 12-week metformin treatment (201.0± 34.8 pg/mL vs 213.1± 34.4 pg/mL, P < 0.05), while insulin resistance was alleviated (ln(HOMA-IR): 1.35± 0.55 vs 1.07± 0.49, P < 0.01).
Conclusion: Metformin reduced circulating levels of secreted frizzled-related protein 5 and improved pathophysiological parameters of T2DM.
Keywords: secreted frizzled-related protein 5, type 2 diabetes mellitus, obesity, insulin resistance, metformin